Madrigal Pharmaceuticals Inc Stock Research

Market Summary

USD280.02-4.86

Market Closed

-1.71%

MDGL Stock Price

MDGL RSI Chart

MDGL Valuation

Market Cap

5.1B

Price/Earnings (Trailing)

-16.27

Price/Sales (Trailing)

2.5K

Price/Free Cashflow

-19.75

MDGL Price/Sales (Trailing)

MDGL Profitability

Return on Equity

-149.63%

Return on Assets

-81.46%

Free Cashflow Yield

-5.06%

MDGL Fundamentals

MDGL Revenue

MDGL Earnings

Earnings (TTM)

-314.7M

Earnings Y/Y

-33.7%

Earnings Q/Q

10.48%

Price Action

52 Week Range

57.21322.67

(Low)(High)

Last 7 days

-0.8%

Last 30 days

-10.2%

Last 90 days

0.3%

Trailing 12 Months

307.7%

MDGL Financial Health

Current Ratio

3.12

Debt/Equity

6.25

Debt/Cashflow

-3.21

MDGL Investor Care

Shares Dilution (1Y)

6.90%

Diluted EPS (TTM)

-18.1

Peers (Alternatives to Madrigal Pharmaceuticals)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	311.1B	1.6B	-10.47%	70.40%	-162.26	199.76	77.54%	1.62%
ABBV	285.4B	56.7B	-9.71%	-7.25%	24.12	4.92	0.03%	-39.22%
REGN	87.6B	12.4B	-9.13%	5.17%	20.2	7.2	-25.07%	-47.28%
VRTX	83.8B	9.2B	-4.53%	18.84%	25.7	9.1	15.86%	32.99%
ALNY	23.2B	1.0B	-6.40%	45.93%	-21.75	22.33	22.88%	-19.27%
SRPT	11.6B	975.7M	1.67%	67.21%	-10.42	11.92	27.41%	-212.78%
UTHR	9.6B	2.0B	-10.84%	-12.99%	13.17	4.84	12.05%	52.86%
MID-CAP
MDGL	5.1B	-	-10.25%	307.66%	-16.27	2.5K	-	-27.52%
BPMC	3.4B	204.6M	10.50%	0.21%	-5.87	16.66	-7.52%	10.65%
RARE	3.4B	363.3M	10.85%	-0.47%	-4.8	9.35	3.39%	-55.81%
MRTX	2.2B	18.9M	-16.27%	-6.81%	-2.93	114.18	-	-16.17%
SMALL-CAP
CYTK	3.6B	-	1.50%	-9.34%	-8.36	38.06	34.30%	-67.22%
CPRX	1.2B	256.5M	-27.45%	57.57%	12.31	4.77	66.85%	120.61%
MGNX	288.8M	165.3M	-32.22%	33.43%	-3.16	1.75	130.70%	57.97%
CRBP	37.4M	-	1.03%	2894.60%	-0.74	19.11	-	-29.84%

Financials for Madrigal Pharmaceuticals

Income Statement (Last 12 Months)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-51.1%	363,000	743,000	1,506,000	2,619,000	4,329,000

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-8.3%	332	363	159	216	223
Current Assets	-8.3%	331	361	157	215	221
Cash Equivalents	-65.8%	113	332	59.00	53.00	42.00
Net PPE	-14.8%	1.00	1.00	1.00	1.00	1.00
Liabilities	10.4%	182	165	148	133	77.00
Current Liabilities	-15.1%	98.00	116	99.00	84.00	77.00
Long Term Debt	-	67.00	-	-	-	-
LT Debt, Non Current	70.4%	84.00	49.00	49.00	49.00	-
Shareholder's Equity	-23.9%	150	197	11.00	84.00	146
Retained Earnings	-8.0%	-1,039	-962	-876	-795	-724
Additional Paid-In Capital	2.6%	1,190	1,160	888	880	871
Shares Outstanding	1.0%	18.00	18.00	17.00	17.00	17.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-15.2%	-259	-224	-214	-200	-190
Share Based Compensation	11.9%	35.00	32.00	30.00	28.00	28.00
Cashflow From Investing	-117.5%	-36.10	207	156	131	84.00
Cashflow From Financing	16.8%	366	313	69.00	90.00	104

Risks for MDGL

What is the probability of a big loss on MDGL?

95.4%

Probability that Madrigal Pharmaceuticals stock will be more than 20% underwater in next one year

89.2%

Probability that Madrigal Pharmaceuticals stock will be more than 30% underwater in next one year.

59.2%

Probability that Madrigal Pharmaceuticals stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MDGL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Madrigal Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for MDGL

Cumulative Returns on MDGL

0.8%

10-Year Cumulative Returns

56.4%

7-Year Cumulative Returns

1.1%

5-Year Cumulative Returns

34.1%

3-Year Cumulative Returns

What are the long-term rolling returns for MDGL?

FIve years rolling returns for Madrigal Pharmaceuticals.

Annualized Returns

Which funds bought or sold MDGL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	reduced	-9.73	-218,464	667,669	-%
2023-05-25	Legato Capital Management LLC	new	-	488,154	488,154	0.09%
2023-05-24	Verity Asset Management, Inc.	added	44.23	60,455	357,091	0.21%
2023-05-23	Capital Impact Advisors, LLC	added	17.85	-11,658	700,616	0.86%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-8.39	-97,397	317,603	-%
2023-05-18	JPMORGAN CHASE & CO	reduced	-1.81	-2,850,000	12,947,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-19.02	-2,033,000	4,240,000	0.01%
2023-05-16	Hudson Bay Capital Management LP	new	-	6,226,080	6,226,080	0.03%
2023-05-16	JANE STREET GROUP, LLC	added	161	15,112,200	27,906,400	0.01%
2023-05-16	FRED ALGER MANAGEMENT, LLC	added	29.44	376,167	5,055,000	0.03%

Latest Funds Activity

Are funds buying MDGL calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own MDGL

No. of Funds

Madrigal Pharmaceuticals News

Schedule 13G FIlings of Madrigal Pharmaceuticals

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	armistice capital, llc	1.21%	208,000	SC 13G/A
Feb 14, 2023	deep track capital, lp	0%	0	SC 13G/A
Feb 14, 2023	baker bros. advisors lp	9.0%	1,545,113	SC 13G/A
Feb 14, 2023	avoro capital advisors llc	9.7%	1,660,000	SC 13G/A
Feb 09, 2023	vanguard group inc	7.40%	1,266,375	SC 13G/A
Feb 06, 2023	wellington management group llp	0.19%	31,830	SC 13G/A
Feb 02, 2023	state street corp	7.37%	1,260,993	SC 13G
Feb 01, 2023	blackrock inc.	5.8%	986,572	SC 13G/A
May 19, 2022	deep track capital, lp	5.37%	917,825	SC 13G
Feb 15, 2022	armistice capital, llc	6.6%	1,124,000	SC 13G

MDGL Fair Value

Show Fair-Value

Recent SEC filings of Madrigal Pharmaceuticals

View All Filings

Date Filed	Form Type	Document
May 09, 2023	8-K	Current Report
May 09, 2023	8-K	Current Report
May 09, 2023	424B5	Prospectus Filed
May 09, 2023	10-Q	Quarterly Report
May 01, 2023	DEFA14A	DEFA14A
May 01, 2023	DEF 14A	DEF 14A
Apr 21, 2023	PRE 14A	PRE 14A
Mar 03, 2023	10-K/A	Annual Report
Mar 02, 2023	4	Insider Trading
Feb 23, 2023	8-K	Current Report

Latest Insider Trading transactions for MDGL

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-01	Waltermire Robert E.	acquired	439,600	87.92	5,000	senior vp, chief pharma dev.
2023-03-01	Waltermire Robert E.	sold	-1,372,080	274	-5,000	senior vp, chief pharma dev.
2023-02-28	Waltermire Robert E.	acquired	439,600	87.92	5,000	senior vp, chief pharma dev.
2023-02-28	Waltermire Robert E.	sold	-1,360,360	272	-5,000	senior vp, chief pharma dev.
2023-01-17	Levy Richard S	acquired	2,316,840	103	22,489	-
2023-01-17	Levy Richard S	sold	-6,592,690	293	-22,489	-
2023-01-16	Howarth Alex G.	acquired	-	-	15,001	chief financial officer
2023-01-16	FRIEDMAN PAUL A	acquired	-	-	26,668	chief executive officer
2023-01-16	Taub Rebecca	acquired	-	-	20,001	pres., r&d, and cmo
2023-01-16	Lynch Brian Joseph	acquired	-	-	15,001	svp and general counsel

About Madrigal Pharmaceuticals

Paul A. Friedman

www.madrigalpharma.com

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ÃƒÅ¸ agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

MDGL Income Statement

2023-03-31

Condensed Consolidated Statements Of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Total revenues
Operating expenses:
Research and development	62,154	47,929
General and administrative	16,182	9,658
Total operating expenses	78,336	57,587
Loss from operations	(78,336)	(57,587)
Interest income	3,776	69
Interest expense	(2,336)	0
Net loss	$ (76,896)	$ (57,518)
Net loss per common share:
Basic net loss per common share	$ (4.23)	$ (3.36)
Diluted net loss per common share	$ (4.23)	$ (3.36)
Basic weighted average number of common shares outstanding	18,187,924	17,103,395
Diluted weighted average number of common shares outstanding	18,187,924	17,103,395

MDGL Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 113,308	$ 331,549
Marketable securities	216,169	27,225
Prepaid expenses and other current assets	1,807	2,595
Total current assets	331,284	361,369
Property and equipment, net	512	601
Right-of-use asset	653	602
Total assets	332,449	362,572
Current liabilities:
Accounts payable	12,128	23,831
Accrued expenses	85,567	91,461
Lease liability	653	602
Total current liabilities	98,348	115,894
Long term liabilities:
Loan payable, net of discount	83,965	49,289
Total long term liabilities	83,965	49,289
Total liabilities	182,313	165,183
Stockholders' equity:
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at March 31, 2023 and December 31, 2022; 2,369,797 and 2,369,797 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively
Common stock, par value $0.0001 per share authorized: 200,000,000 at March 31, 2023 and December 31, 2022; 18,283,074 and 18,102,523 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	2	2
Additional paid-in-capital	1,189,776	1,160,079
Accumulated other comprehensive loss	(86)	(32)
Accumulated deficit	(1,039,556)	(962,660)
Total stockholders' equity	150,136	197,389
Total liabilities and stockholders' equity	$ 332,449	$ 362,572